HER2阳性早期乳腺癌治疗年度进展

Annual progress on the treatment for HER2 positive early-stage breast cancer

临床治疗指南推荐曲妥珠单抗作为HER2+早期乳腺癌的标准辅助治疗手段之一。在此基础之上,研究者继续尝试新的突破:一方面部分研究者试图通过双靶向治疗、延长用药期限等手段,进一步降低HER2+早期乳腺癌复发率;另一方面,其他研究者也在尝试缩短靶向治疗时间、减少传统化疗药物的使用等,以减少不必要的治疗及其带来的毒副作用。本文将对近期大型临床研究结果进行总结,围绕四个关于早期乳腺癌抗HER2辅助治疗的热点问题:HER2低表达患者是否需要抗HER2治疗?能否缩短抗HER2治疗的疗程?是否需要加强HER2+早期乳腺癌的靶向治疗?是否可以减少化疗药物的使用?为临床医生合理选择抗HER2靶向治疗提供参考。

Clinical guidelines recommend trastuzumab as one of the standard adjuvant treatments for early-stage HER2-positive breast cancer.Researchers are continuing to look for new potential breakthroughs based on the previous studies:on one hand,scientists try to reduce the recurrence rate for early-stage HER2-positive breast cancer by adding a second HER2targeted treatment or extending therapy duration,on the other hand,other researchers attempt to reduce side-effects of unnecessary medical treatment by cutting the dosage of chemotherapy or using shorter course chemotherapy.In this review,we summarize some large clinical study results in recent years and focus on those following topics:1.Is anti-HER2targeted therapy required for patients with HER2-Low expression breast cancer?2.Can we use shortcourse anti-HER2therapy-3.Will it improve clinical outcome by using two HER2Blocker together for the treatment of early-stage HER2-positive breast cancer-4.Will it be able to reduce chemotherapy?This review will provide new insight and recommendations for oncologists and clinicians on HER2-targeted therapy for early-stage HER2-positive breast cancer.